UNASSIGNED: Minimally modified low density lipoprotein (mmLDL) is a risk factor for @entity65 . However, no studies examining the effect of mmLDL on vascular smooth muscle receptors have been released. The current study investigated the effect of mmLDL on the mesenteric artery a1 adrenoceptor and the molecular mechanisms. @entity19 were divided into the normal saline (NS), mmLDL, and mmLDL+ @entity5732 groups. In the mmLDL+ @entity5732 group, the animals were subjected to an intravenous tail injection of mmLDL and an intraperitoneal injection of @entity5732 . Vascular tension caused by @entity1063 (NA) in mesenteric arteries was measured with a sensitive myograph system. The serum levels of oxLDL, @entity637 , and @entity635 were detected using enzyme-linked immunosorbent assays. The expressions of the a1 adrenoceptor, the a2 adrenoceptor, @entity637 , @entity635 , and pERK1/2 were detected using real-time polymerase chain reactions and Western blot analysis. Compared with the NS group, the mmLDL group exhibited a noticeably enhanced NA shrinkage dose-response curve and a significantly increased Emax value (P<0.01). @entity3159 (a1 adrenoceptor antagonist) caused a noticeable right shift of the dose-response curve. @entity5732 inhibited the increases in the serum levels and vessel wall expression of @entity635 and @entity637 and enhanced the NA shrinkage dose-response curve caused by mmLDL, as observed by a significantly decreased Emax value (P<0.01). It inhibited the increased a1 adrenoceptor expression caused by mmLDL. The serum levels of @entity635 and @entity637 demonstrated a positive correlation with the NA-induced maximum shrinkage percentage. @entity5732 inhibited the mmLDL-induced increase in the pERK1/2 protein level in the vessel wall. In conclusion, mmLDL increased the serum levels of @entity635 and @entity637 in vivo by activating the @entity8837 pathway, which resulted in a1 receptor-mediated vasoconstriction and an increase in the expression of a1 adrenoceptor. The results of this study may provide new ideas for the prevention and cure of @entity65 in the future.

The XXXX pathway participates in the upregulation of the expression of mesenteric artery a1 receptors by intravenous tail injections of mmLDL in @entity19 .

@entity5732 :: ('MESH:C113580', 'Chemical') :: ['U0126'] @entity19 :: ('10090', 'Species') :: ['Mice'] @entity635 :: ('16176(Tax:10090)', 'Gene') :: ['IL-1b'] @entity3159 :: ('MESH:D011224', 'Chemical') :: ['Prazosin'] @entity1063 :: ('MESH:D009638', 'Chemical') :: ['noradrenaline'] @entity637 :: ('21926(Tax:10090)', 'Gene') :: ['TNF-a'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases'] @entity8837 :: ('26417;26413', 'Gene') :: ['ERK1/2']
@entity8837 :: (26417;26413,Gene) :: ['ERK1/2']
